Tamara Pringsheim1, Yolanda Holler-Managan1, Michael S Okun1, Joseph Jankovic1, John Piacentini1, Andrea E Cavanna1, Davide Martino1, Kirsten Müller-Vahl1, Douglas W Woods1, Michael Robinson1, Elizabeth Jarvie1, Veit Roessner1, Maryam Oskoui1. 1. From the Department of Clinical Neurosciences, Psychiatry, Pediatrics and Community Health Sciences (T.P., D.M.), Cumming School of Medicine, University of Calgary, Alberta, Canada; Department of Pediatrics (Neurology) (Y.H.-M.), Northwestern University Feinberg School of Medicine, Chicago, IL; Departments of Neurology and Neurosurgery (M.S.O.), Fixel Center for Neurological Diseases, University of Florida, Gainesville; Department of Neurology (J.J.), Baylor College of Medicine, Houston, TX; Department of Psychiatry and Biobehavioral Sciences (J.P.), Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles; Department of Neuropsychiatry (A.E.C.), BSMHFT, University of Birmingham and Aston University, UK; Department of Psychiatry, Social Psychiatry, and Psychotherapy (K.M.-V.), Hannover Medical School, Germany; Department of Psychology (D.W.W.), Marquette University, Milwaukee, WI; Massachusetts Chapter (M.R.), Tourette Association of America, Bayside, NY; Waisman Center (E.J.), University Center for Excellence in Developmental Disabilities, University of Wisconsin, Madison; Technische Universitaet Dresden (V.R.), Germany; and Departments of Pediatric and Neurology/Neurosurgery (M.O.), McGill University, Montréal, Canada.
Abstract
OBJECTIVE: To systematically evaluate the efficacy of treatments for tics and the risks associated with their use. METHODS: This project followed the methodologies outlined in the 2011 edition of the American Academy of Neurology's guideline development process manual. We included systematic reviews and randomized controlled trials on the treatment of tics that included at least 20 participants (10 participants if a crossover trial), except for neurostimulation trials, for which no minimum sample size was required. To obtain additional information on drug safety, we included cohort studies or case series that specifically evaluated adverse drug effects in individuals with tics. RESULTS: There was high confidence that the Comprehensive Behavioral Intervention for Tics was more likely than psychoeducation and supportive therapy to reduce tics. There was moderate confidence that haloperidol, risperidone, aripiprazole, tiapride, clonidine, onabotulinumtoxinA injections, 5-ling granule, Ningdong granule, and deep brain stimulation of the globus pallidus were probably more likely than placebo to reduce tics. There was low confidence that pimozide, ziprasidone, metoclopramide, guanfacine, topiramate, and tetrahydrocannabinol were possibly more likely than placebo to reduce tics. Evidence of harm associated with various treatments was also demonstrated, including weight gain, drug-induced movement disorders, elevated prolactin levels, sedation, and effects on heart rate, blood pressure, and ECGs. CONCLUSIONS: There is evidence to support the efficacy of various medical, behavioral, and neurostimulation interventions for the treatment of tics. Both the efficacy and harms associated with interventions must be considered in making treatment recommendations.
OBJECTIVE: To systematically evaluate the efficacy of treatments for tics and the risks associated with their use. METHODS: This project followed the methodologies outlined in the 2011 edition of the American Academy of Neurology's guideline development process manual. We included systematic reviews and randomized controlled trials on the treatment of tics that included at least 20 participants (10 participants if a crossover trial), except for neurostimulation trials, for which no minimum sample size was required. To obtain additional information on drug safety, we included cohort studies or case series that specifically evaluated adverse drug effects in individuals with tics. RESULTS: There was high confidence that the Comprehensive Behavioral Intervention for Tics was more likely than psychoeducation and supportive therapy to reduce tics. There was moderate confidence that haloperidol, risperidone, aripiprazole, tiapride, clonidine, onabotulinumtoxinA injections, 5-ling granule, Ningdong granule, and deep brain stimulation of the globus pallidus were probably more likely than placebo to reduce tics. There was low confidence that pimozide, ziprasidone, metoclopramide, guanfacine, topiramate, and tetrahydrocannabinol were possibly more likely than placebo to reduce tics. Evidence of harm associated with various treatments was also demonstrated, including weight gain, drug-induced movement disorders, elevated prolactin levels, sedation, and effects on heart rate, blood pressure, and ECGs. CONCLUSIONS: There is evidence to support the efficacy of various medical, behavioral, and neurostimulation interventions for the treatment of tics. Both the efficacy and harms associated with interventions must be considered in making treatment recommendations.
Authors: L Scahill; P B Chappell; Y S Kim; R T Schultz; L Katsovich; E Shepherd; A F Arnsten; D J Cohen; J F Leckman Journal: Am J Psychiatry Date: 2001-07 Impact factor: 18.112
Authors: Mary M Robertson; Valsamma Eapen; Harvey S Singer; Davide Martino; Jeremiah M Scharf; Peristera Paschou; Veit Roessner; Douglas W Woods; Marwan Hariz; Carol A Mathews; Rudi Črnčec; James F Leckman Journal: Nat Rev Dis Primers Date: 2017-02-02 Impact factor: 52.329
Authors: A A Silver; R D Shytle; K H Sheehan; D V Sheehan; A Ramos; P R Sanberg Journal: J Am Acad Child Adolesc Psychiatry Date: 2001-09 Impact factor: 8.829
Authors: K R Müller-Vahl; U Schneider; A Koblenz; M Jöbges; H Kolbe; T Daldrup; H M Emrich Journal: Pharmacopsychiatry Date: 2002-03 Impact factor: 5.788
Authors: Vilma Gabbay; James S Babb; Rachel G Klein; Aviva M Panzer; Yisrael Katz; Carmen M Alonso; Eva Petkova; Jing Wang; Barbara J Coffey Journal: Pediatrics Date: 2012-05-14 Impact factor: 7.124
Authors: Rebecca H Bitsko; Angelika H Claussen; Jesse Lichstein; Lindsey I Black; Sherry Everett Jones; Melissa L Danielson; Jennifer M Hoenig; Shane P Davis Jack; Debra J Brody; Shiromani Gyawali; Matthew J Maenner; Margaret Warner; Kristin M Holland; Ruth Perou; Alex E Crosby; Stephen J Blumberg; Shelli Avenevoli; Jennifer W Kaminski; Reem M Ghandour Journal: MMWR Suppl Date: 2022-02-25
Authors: Michel Sáenz-Farret; Marina A J Tijssen; Dawn Eliashiv; Robert S Fisher; Kapil Sethi; Alfonso Fasano Journal: CNS Drugs Date: 2022-07-21 Impact factor: 6.497
Authors: Sara Beth Wolicki; Rebecca H Bitsko; Joseph R Holbrook; Melissa L Danielson; Benjamin Zablotsky; Lawrence Scahill; John T Walkup; Douglas W Woods; Jonathan W Mink Journal: Psychiatry Res Date: 2020-08-18 Impact factor: 3.222
Authors: Joseph F McGuire; John Piacentini; Eric A Storch; Emily J Ricketts; Douglas W Woods; Alan L Peterson; John T Walkup; Sabine Wilhelm; Kesley Ramsey; Joey K-Y Essoe; Michael B Himle; Adam B Lewin; Susanna Chang; Tanya K Murphy; James T McCracken; Lawrence Scahill Journal: J Psychiatr Res Date: 2020-12-13 Impact factor: 4.791